Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.36 |
| ▸ | ADH1B | P00325 | 1/20 | 0.35 |
| ▸ | ADH1C | P00326 | 1/20 | 0.35 |
| ▸ | ADH1A | P07327 | 1/20 | 0.35 |
| ▸ | ADH4 | P08319 | 1/20 | 0.35 |
| ▸ | ADH7 | P40394 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 4/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.34 |
| ▸ | GAPDH | P04406 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28153709 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL28161642 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL28277698 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL3883638 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL12484960 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL28161036 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL28154776 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL28154824 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL11289007 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 | |
| SCHEMBL11177604 | 0.97 | TSHR (0.50) | TSHRSMN1; SMN2OPRM1LMNADNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157360-B1 | TCDTA-DERIVED FE(III) COMPLEXES FOR USE IN MAGNET RESONANCE IMAGING WITH LIVER AND KIDNEY EXCRETION | UNIV BERLIN CHARITE (DE) | 2024-02-28 | — | — | EP | disclosed |
| EP-4045095-B1 | IRON (III) COMPLEXES WITH NOVEL CONTRAST PROPERTIES FOR MAGNETIC RESONANCE IMAGING | UNIV BERLIN CHARITE (DE) | 2023-08-02 | — | — | EP | disclosed |
| EP-4157360-A1 | TCDTA-DERIVED FE(III) COMPLEXES FOR USE IN MAGNET RESONANCE IMAGING WITH LIVER AND KIDNEY EXCRETION | Charité - Universitätsmedizin Berlin (DE) | 2023-04-05 | — | — | EP | disclosed |
| US-20220331454-A1 | IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2022-10-20 | — | — | US | disclosed |
| EP-4045095-A1 | IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING | Charité - Universitätsmedizin Berlin (DE) | 2022-08-24 | — | — | EP | disclosed |
| CN-114634533-A | Organometallic compound, organic light emitting device including the same, and diagnostic composition including the organometallic compound | 三星电子株式会社 | 2022-06-17 | — | — | CN | disclosed |
| WO-2021239687-A1 | TCDTA-DERIVED FE(III) COMPLEXES FOR USE IN MAGNET RESONANCE IMAGING WITH LIVER AND KIDNEY EXCRETION | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2021-12-02 | — | — | WO | disclosed |
| EP-3915589-A1 | TCDTA-DERIVED FE(III) COMPLEXES FOR USE IN MAGNET RESONANCE IMAGING WITH LIVER AND KIDNEY EXCRETION | Charité - Universitätsmedizin Berlin (DE) | 2021-12-01 | — | — | EP | disclosed |
| WO-2021074368-A1 | IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING | CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) | 2021-04-22 | — | — | WO | disclosed |
| EP-3808381-A1 | IRON (III) COMPLEXES WITH NOVEL CONTRAST PROPERTIES FOR MAGNETIC RESONANCE IMAGING | Charité - Universitätsmedizin Berlin (DE) | 2021-04-21 | — | — | EP | disclosed |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | EISAI CO., LTD. | 2005-01-06 | — | — | US | disclosed |
| WO-2003026591-A9 | MODIFICATION OF FEEDING BEHAVIOR | IMP COLLEGE INNOVATIONS LTD (GB) | 2004-07-08 | — | — | WO | disclosed |
| EP-1408040-A1 | Tricyclic fused heterocyclic compounds as CRFantagonists | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| CN-1409713-A | Tricyclic fused heterocyclic compound, process for producing the same, and pharmaceutical comprising the same | EISAI CO LTD (JP) | 2003-04-09 | — | — | CN | disclosed |
| EP-1238979-A1 | FUSED HETEROTRICYCLIC COMPOUNDS, PROCESS FOR PREPARING THE COMPOUNDS AND DRUGS CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
| US-5750540-A | SIDE EFFECT REDUCTION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1998-05-12 | — | — | US | disclosed |
| US-5230802-A | Liquid ion exchanger of alkyl 2,3-bis(alkanoyloxy)butanediote and ion exchange process | PHILIP MORRIS INCORPORATED (US) | 1993-07-27 | — | — | US | disclosed |
| EP-0514201-A1 | Separation process using organic acids and novel organic acids | Philip Morris Products Inc. (US) | 1992-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220331454-A1 | IRON(III) COMPLEXES HAVING NEW CONTRAST AGENT PROPERTIES, FOR MAGNETIC RESONANCE IMAGING | TFRC, SLC40A1, FTH1 | TSHR 1088/4885SMN1; SMN2 2320/4885OPRM1 1629/4885 |
| US-20030078277-A1 | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | NR3C2, CRHR1, CRHR2 | TSHR 140/4885SMN1; SMN2 3994/4885OPRM1 179/4885 |
| US-20050004159-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | TSHR 47/4885SMN1; SMN2 3935/4885OPRM1 492/4885 |
| US-20050004147-A1 | Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it | CRHR2, CRHR1, NR3C2 | TSHR 47/4885SMN1; SMN2 3935/4885OPRM1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.